News Ozempic patient blinded by NAION sues Novo Nordisk Novo Nordisk has seen its first lawsuit over the proposed link between Ozempic and the rare eye disorder NAION.
News Trump blocks plan for Medicare to cover weight-loss drugs A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White House.
News ACC25: Ozempic shows its value in PAD Novo Nordisk's Ozempic has been shown to improve walking distance in people with diabetes and peripheral artery disease in the STRIDE trial.
Market Access UK weight loss market: M&A opportunities Recent advancements in weight-loss interventions are transforming the healthcare landscape and presenting new M&A opportunities
News Novo Nordisk looks east for another obesity therapy Novo Nordisk has moved to shore up its obesity pipeline with a $2bn licensing deal for a triple agonist developed by China's United Biotechnology.
News Novo Nordisk returns to ABPI fold after two-year suspension Novo Nordisk has reached the end of its two-year suspension from the ABPI for breaches of its code of practice after making "sustained improvements."
News Lilly's 'triple G' retatrutide aces crucial obesity trial Lilly's retatrutide achieved weight loss of more than 30% at two years in a new trial, firming up its credentials as a next-generation obesity drug.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
